The expression of VEGFR1, VEGFR2, and VEGFR3 has also been demonstrated to vary between the different stages of cervical (Van Trappen et al., 2003), prostate (Grivas et al., 2016) and ovarian (Klasa-Mazurkiewicz et al., 2011) cancers, with VEGFR3 being commonly overexpressed in the later stages. Here, FLT1 is linked to cancer.